- Accession Number:
- Form Type:
- Zero Holdings:
- Publication Time:
- 2020-03-18 17:08:39
- Reporting Period:
- Accepted Time:
- 2020-03-18 17:08:39
- SEC Url:
- Form 4 Filing
|Cik||Name||Symbol||Sector (SIC)||IRS No|
|1510487||Principia Biopharma Inc.||PRNB||Pharmaceutical Preparations (2834)||263487603|
|Cik||Name||Reported Address||Insider Title||Director||Officer||Large Shareholder||Other|
|1751790||Stefani Wolff||C/o Principia Biopharma Inc. |
220 E. Grand Avenue
South San Francisco CA 94080
|Chief Development Officer||No||Yes||No||No|
|Sec. Name||Acquisiton - Disposition||Date||Amount||Price||Remaning Holdings||Equity Swap Involved||Form Type||Code||Nature of Ownership||Explanation|
|Equity Swap Involved||Form Type||Code||Nature of Ownership||Explanation|
|Sec. Name||Sec. Type||Acquisiton - Disposition||Date||Amount||Price||Amount - 2||Price - 2|
|Common Stock||Employee Stock Option (right to buy)||Disposition||2020-03-16||5,504||$0.00||5,504||$4.54|
|Remaning Holdings||Exercise Date||Expiration Date||Equity Swap Involved||Transaction Form Type||Transaction Code||Nature of Ownership|
- The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- Represents the weighted average sales price per share. The shares sold at prices ranging from $45.05 to $46.01 per share. Upon request by the Commission staff, Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
- Represents the weighted average sales price per share. The shares sold at prices ranging from $46.08 to $46.60 per share. Upon request by the Commission staff, Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
- The stock option vested and became exercisable as to 25% of the shares subject to the option on July 1, 2017, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.